Day One Biopharmaceuticals (DAWN) has issued an update.
Day One Biopharmaceuticals, Inc. received FDA accelerated approval for OJEMDA™, a drug treating a common childhood brain tumor known as pediatric low-grade glioma (pLGG). The approval, based on promising trial results, allows patients aged six months and older to receive the drug, which has shown significant efficacy and manageable side effects. Additionally, the company secured a rare pediatric disease priority review voucher, highlighting the importance of this new treatment in the fight against childhood cancer.
Learn more about DAWN stock on TipRanks’ Stock Analysis page.
